These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 22110663)
1. S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer. Nawroth R; Stellwagen F; Schulz WA; Stoehr R; Hartmann A; Krause BJ; Gschwend JE; Retz M PLoS One; 2011; 6(11):e27509. PubMed ID: 22110663 [TBL] [Abstract][Full Text] [Related]
2. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma. Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319 [TBL] [Abstract][Full Text] [Related]
3. Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy. Sathe A; Chalaud G; Oppolzer I; Wong KY; von Busch M; Schmid SC; Tong Z; Retz M; Gschwend JE; Schulz WA; Nawroth R PLoS One; 2018; 13(1):e0190854. PubMed ID: 29357370 [TBL] [Abstract][Full Text] [Related]
4. Dual inhibition by S6K1 and Elf4E is essential for controlling cellular growth and invasion in bladder cancer. Kyou Kwon J; Kim SJ; Hoon Kim J; Mee Lee K; Ho Chang I Urol Oncol; 2014 Jan; 32(1):51.e27-35. PubMed ID: 24239466 [TBL] [Abstract][Full Text] [Related]
5. Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells. Zeng Q; Qin S; Zhang H; Liu B; Qin J; Wang X; Zhang R; Liu C; Dong X; Zhang S; Huang S; Chen L J Cell Physiol; 2018 Jan; 233(1):516-529. PubMed ID: 28300280 [TBL] [Abstract][Full Text] [Related]
6. Determinants of rapamycin sensitivity in breast cancer cells. Noh WC; Mondesire WH; Peng J; Jian W; Zhang H; Dong J; Mills GB; Hung MC; Meric-Bernstam F Clin Cancer Res; 2004 Feb; 10(3):1013-23. PubMed ID: 14871980 [TBL] [Abstract][Full Text] [Related]
7. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. Liu L; Li F; Cardelli JA; Martin KA; Blenis J; Huang S Oncogene; 2006 Nov; 25(53):7029-40. PubMed ID: 16715128 [TBL] [Abstract][Full Text] [Related]
8. Activation of AMPK and inactivation of Akt result in suppression of mTOR-mediated S6K1 and 4E-BP1 pathways leading to neuronal cell death in in vitro models of Parkinson's disease. Xu Y; Liu C; Chen S; Ye Y; Guo M; Ren Q; Liu L; Zhang H; Xu C; Zhou Q; Huang S; Chen L Cell Signal; 2014 Aug; 26(8):1680-1689. PubMed ID: 24726895 [TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of phosphatidylinositol 3-kinase/Akt and mammalian target of rapamycin signaling in human nonsmall cell lung cancer cells by a dietary flavonoid fisetin. Khan N; Afaq F; Khusro FH; Mustafa Adhami V; Suh Y; Mukhtar H Int J Cancer; 2012 Apr; 130(7):1695-705. PubMed ID: 21618507 [TBL] [Abstract][Full Text] [Related]
10. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Xu G; Zhang W; Bertram P; Zheng XF; McLeod H Int J Oncol; 2004 Apr; 24(4):893-900. PubMed ID: 15010827 [TBL] [Abstract][Full Text] [Related]
11. Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion. Chen L; Xu B; Liu L; Liu C; Luo Y; Chen X; Barzegar M; Chung J; Huang S Oncotarget; 2015 Mar; 6(9):7136-50. PubMed ID: 25762619 [TBL] [Abstract][Full Text] [Related]
12. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma. Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608 [TBL] [Abstract][Full Text] [Related]
13. Distinct role of 4E-BP1 and S6K1 in regulating autophagy and hepatitis B virus (HBV) replication. Gao Q; Hou B; Yang H; Jiang X Life Sci; 2019 Mar; 220():1-7. PubMed ID: 30690083 [TBL] [Abstract][Full Text] [Related]
14. Significance of 4E-binding protein 1 as a therapeutic target for invasive urothelial carcinoma of the bladder. Nishikawa M; Miyake H; Behnsawy HM; Fujisawa M Urol Oncol; 2015 Apr; 33(4):166.e9-15. PubMed ID: 25618298 [TBL] [Abstract][Full Text] [Related]
15. Rotenone induction of hydrogen peroxide inhibits mTOR-mediated S6K1 and 4E-BP1/eIF4E pathways, leading to neuronal apoptosis. Zhou Q; Liu C; Liu W; Zhang H; Zhang R; Liu J; Zhang J; Xu C; Liu L; Huang S; Chen L Toxicol Sci; 2015 Jan; 143(1):81-96. PubMed ID: 25304210 [TBL] [Abstract][Full Text] [Related]
16. Prolactin activates mammalian target-of-rapamycin through phosphatidylinositol 3-kinase and stimulates phosphorylation of p70S6K and 4E-binding protein-1 in lymphoma cells. Bishop JD; Nien WL; Dauphinee SM; Too CK J Endocrinol; 2006 Aug; 190(2):307-12. PubMed ID: 16899564 [TBL] [Abstract][Full Text] [Related]
17. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. Shoji K; Oda K; Kashiyama T; Ikeda Y; Nakagawa S; Sone K; Miyamoto Y; Hiraike H; Tanikawa M; Miyasaka A; Koso T; Matsumoto Y; Wada-Hiraike O; Kawana K; Kuramoto H; McCormick F; Aburatani H; Yano T; Kozuma S; Taketani Y PLoS One; 2012; 7(5):e37431. PubMed ID: 22662154 [TBL] [Abstract][Full Text] [Related]
18. Concurrent inhibition of PI3-kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1. Zang C; Eucker J; Liu H; Müller A; Possinger K; Scholz CW Cancer Lett; 2013 Oct; 339(2):288-97. PubMed ID: 23200668 [TBL] [Abstract][Full Text] [Related]
19. L-threonine regulates G1/S phase transition of mouse embryonic stem cells via PI3K/Akt, MAPKs, and mTORC pathways. Ryu JM; Han HJ J Biol Chem; 2011 Jul; 286(27):23667-78. PubMed ID: 21550972 [TBL] [Abstract][Full Text] [Related]
20. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]